GLP1R and type 2 diabetes mellitus: These data suggest that physicians may be preferentially selecting patients with type 1 diabetes thought to benefit most from either cardio-renal benefits of SGLT2i therapy or the weight reduction associated with GLP-1 RA, established in type 2 diabetes [17].